Tarsus Pharmaceuticals, Inc. (TARS) fundamentals score
Tarsus Pharmaceuticals is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It launcheds XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S. Food and Drug Administration (“FDA”) approval in July 2023.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 5.9 out of 10, Mixed fundamentals
- Growth: 5.0/10
- Profitability: 4.7/10
- Financial health: 7.2/10
- Earnings quality: 5.8/10
- Valuation: 8.0/10
Scores are calculated from Tarsus Pharmaceuticals, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10